Literature DB >> 20405138

The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.

Kezhong Zhang1, Yanyin Zeng, Chunjie Song, Yu Fu, Qi Wan.   

Abstract

This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD). Twenty-four patients with MSA-p and 26 cases with PD entered the study. They were submitted to treatments of clonidine, arginine and a combination of the two in a random manner on three different nonconsecutive days. The GH peak in serum at different times was evaluated and used as a primary variable for analysis of the stimulation test. By ROC analysis, we compared the sensitivity and specificity of tests of clonidine, arginine and both combined. After clonidine administration, the maximal average was significantly lower in patients with MSA-p than in those with PD (3.62 +/- 0.81 vs. 6.91 +/- 1.13; P < 0.05) with a sensitivity and specificity of 82.61 and 76.92%. After arginine administration, the maximal average GH concentration in serum at 30 min was also significantly lower in patients with MSA-p than in those with PD (4.07 +/- 0.80 vs. 7.89 +/- 1.29; P < 0.05) with a sensitivity and specificity of 78.26 and 73.08%. The sensitivity and specificity in differentiating MSA-p from PD was higher in the clonidine GH stimulation test than in the arginine GH stimulation test. However, when the clonidine and arginine were applied combined, the contrast of the maximal average GH concentration in serum in two groups was markedly increased (5.02 +/- 1.12 vs. 10.75 +/- 1.11; P < 0.05) with a sensitivity and specificity of 73.91 and 92.31%, and the specificity was notably increased in the combined GH stimulation test. Compared to the arginine GH stimulation test, the clonidine GH stimulation displayed a higher sensitivity and specificity; combined GH stimulation test of clonidine plus arginine could significantly enhance the specificity in differential diagnosis of MSA-p from PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405138     DOI: 10.1007/s00415-010-5556-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

1.  Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy.

Authors:  S Braune; M Reinhardt; R Schnitzer; A Riedel; C H Lücking
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

Review 2.  Neuroendocrine control of growth hormone secretion.

Authors:  E E Müller; V Locatelli; D Cocchi
Journal:  Physiol Rev       Date:  1999-04       Impact factor: 37.312

3.  Value of sphincter electromyography in the diagnosis of multiple system atrophy.

Authors:  J Palace; V A Chandiramani; C J Fowler
Journal:  Muscle Nerve       Date:  1997-11       Impact factor: 3.217

Review 4.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

Review 5.  Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease.

Authors:  Maria Teresa Pellecchia; Rosario Pivonello; Annamaria Colao; Paolo Barone
Journal:  Clin Med Res       Date:  2006-12

6.  Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine.

Authors:  J R Kimber; L Watson; C J Mathias
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease.

Authors:  B Barbiroli; P Martinelli; A Patuelli; R Lodi; S Iotti; P Cortelli; P Montagna
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

9.  Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease.

Authors:  C Colosimo; A Albanese; A J Hughes; V M de Bruin; A J Lees
Journal:  Arch Neurol       Date:  1995-03

10.  Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases.

Authors:  E G Spokes; R Bannister; D R Oppenheimer
Journal:  J Neurol Sci       Date:  1979-09       Impact factor: 3.181

View more
  2 in total

1.  Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy.

Authors:  C Alves Do Rego; I J Namer; C Marcel; F Lefebvre; O Lagha-Boukbiza; M Renaud; C Tranchant; M Anheim
Journal:  J Neurol       Date:  2018-06-28       Impact factor: 4.849

2.  Clonidine GH stimulation test to differentiate MSA from idiopathic late onset cerebellar ataxia: a prospective, controlled study.

Authors:  C Bonnard; T Wirth; O Gebus; P Fahrer; S Montaut; L Robelin; N Tuzin; C Tranchant; Mathieu Anheim
Journal:  J Neurol       Date:  2020-02-07       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.